I cannot provide information about the follow-up duration in the RAPID trial for Cardamyst (Etripamil) because none of the evidence provided contains specific follow-up duration data for the RAPID trial itself.
What the Evidence Shows
The provided evidence includes multiple references to the RAPID trial 1, 2, 3, but these sources focus on:
- Trial design and rationale - describing the study methodology and objectives 2
- Acute efficacy outcomes - reporting conversion rates within 30 minutes of etripamil administration 3
- Immediate safety monitoring - documenting adverse events within 24 hours of treatment 3
Related Long-Term Data Available
The NODE-302 open-label extension study, which is distinct from the RAPID trial, did report long-term follow-up data:
- Median follow-up of 232 days (range 8-584 days) among 105 patients who self-administered etripamil for perceived PSVT episodes 4
However, this represents a different study protocol focused on repeated self-treatment over time, not the primary RAPID trial follow-up duration.
Key Distinction
The RAPID trial was designed as an event-driven study evaluating acute conversion of single PSVT episodes 2, 3, with the primary endpoint measured within 30 minutes of drug administration 3. The trial methodology did not emphasize extended follow-up duration in the way traditional cardiovascular outcome trials do, as the focus was on immediate arrhythmia termination rather than long-term clinical outcomes.